Light Modulation (LM™ LLLT) & Optimal Power Energy (OPE™ IPL), for the optimal, non-invasive treatment of Dry Eye Disease (DED)
eye-light®
Solutions for dry eye and more...
NEW
Dry AMD Treatment
The integration of cutting-edge technology from Espansione Group into optometric practice.
Age-related Macular Degeneration (AMD) remains the leading cause of irreversible blindness in the developed world, particularly in its advanced stages. This makes innovations in treatment both urgent and critical.
How do we address this challenge?
ENTER
Photobiomodulation Therapy
This new ground-breaking light-based treatment delivered through the advanced eye-light® device, to address this challenge. This therapy leverages light energy to stimulate cellular repair and regeneration, offering a scientifically validated and non-invasive approach to managing dry AMD.
Why is this a game-changer?
PBM specifically targets AREDS 3 and lower classifications, addressing significant gaps in current treatment protocols. By slowing disease progression, preserving vision, and enhancing patient quality of life, this innovation represents a significant leap forward for eye care professionals and their patients alike.
Interested in being part of this revolution?
Topcon is proud to be the exclusive distributor of Eye-light® solutions in the UK and Ireland. If you’d like to stay ahead of the curve, today, and we’ll keep you informed about commercial availability
FIND OUT MORE about LightWave I Clinical Trial and Efficacy of Light Modulation™ LLLT (PBM) on eye-light® for dry AMD
Article: Photobiomodulation-induced choriocapillaris perfusion enhancement and outer retinal remodeling in intermediate age-related macular degeneration: a promising therapeutic approach with short-term results
eye-light®
The eye-light® solution features both core technologies; Light Modulation Low Level Light Therapy (LM™ LLLT) and Optimal Power Energy™ Intense Pulse Light, (OPE™ IPL) giving an optimal, non-invasive treatment for most ocular surface conditions from Dry Eye Disease (DED) induced by Meibomian Gland Dysfunction (MGD) to Sjogren’s Syndrome, and now dryAMD with the NEW dry AMD masks.
mgd mask®
Focused on the unique benefits of LM™ LLLT technology for the treatment of most ocular surface diseases and now dryAMD with the NEW dry AMD masks.
my-mask®
Designed with convenience in mind, miniaturising the LM™ LLLT technology into such a portable, small package was a challenge, to provide a convenient yet powerful solution to benefit from light-based therapy wherever, so patients can continue treatment in the comfort of their own home.
The 2 different colour AMD treatment masks
Red light . (630 nm) boosts ATP production, restores mitochondria and increases metabolic activity, inhibits inflammation and cell death.
Yellow light . (590 nm) naturally inhibits VEGF expression, reducing blood vessel formation linked to wet AMD.
The 3 different colours of the original LM™ LLLT treatment masks:-
Contact us for a demonstration [email protected]
Find out more https://espansionegroup.it/solutions/